- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Generic Drugs
Impax Laboratories Inc
+ Add to WatchlistIPXL:US
18.6000 USD 0.0100 0.05%
Share
As of 20:10:00 ET on 05/23/2013.
More on IPXL
News for Impax Laboratories Inc (IPXL)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Endo Loses Bid to Stop Sales of Generic Painkiller Rivals
- ArcelorMittal, Bayer, OxyContin: Intellectual Property
- FDA Bans Generics of Purdue's Older OxyContin Painkiller
- Impax Shares Plummet as FDA Finds Manufacturing Issues
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Shire Falls Most Since June on Adderall XR Competition
- Google, Merck, Gruyere, Newzbin2: Intellectual Property
- Merck Wins Ruling to Block Mylan’s Copy of Zetia, Vytorin
- Tougher Limits on Most-Used Pain Pills Backed by Panel
- Impax Laboratories Falls as FDA Rejects Parkinson’s Drug
- Impax Fails to Win Approval for Parkinson’s Drug
- Endo Health Loses Suit to Stop Sales of Generic Painkiller
- FDA Seeks to Balance Opioid Pain Needs With Addict Risks
- Endo Health Sues FDA Over Safety of Painkiller Opana
- Gevo, Alnylam, Megaupload, Google: Intellectual Property
- Impax Board of Directors Establishes Compliance Committee Published May 20, 2013
- Impax Laboratories to Present at the UBS Global Healthcare Conference Published May 20, 2013
- Impax Laboratories Launches Authorized Generic of Zomig (zolmitriptan) Tablets and Orally Disintegrating Tablets in the U.S. Published May 17, 2013
- Impax Laboratories to Present at the Bank of America Merrill Lynch 2013 Health Care Conference Published May 10, 2013
- IMPAX LABORATORIES 96 HOUR ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Published May 03, 2013
- Impax Laboratories Reports First Quarter 2013 Results Published May 01, 2013
- Impax Pharmaceuticals and GlaxoSmithKline Terminate Their Collaboration on IPX066 (RYTARYTM) Published Apr 29, 2013
- Law Offices of Howard G. Smith Encourages Investors to Inquire About a Lead Plaintiff Position in the Class Action Lawsuit Published Apr 28, 2013
- Shire Settles All Pending Litigation with Actavis and Watson Concerning INTUNIV® Published Apr 25, 2013
- SHIRE PLC: Shire Settles INTUNIV Litigation with Actavis and Watson Published Apr 25, 2013
- UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Impax Laboratories Inc. of Class Published Apr 23, 2013
- Jyothy Woos Urban Women to Raise Deodorant Sales Sixfold
- India Said to Seek Review of U.S. Court Ruling Papers on Ranbaxy
- Nintendo, P&G, Interflora: Intellectual Property
- Kasowitz Benson, Eversheds, Latham: Business of Law
- Actavis Lowers Tax Rate to 17% After Warner Chilcott Deal
- Sanofi, Roll Global, Heineken, WWE: Intellectual Property
- Teva Bets on Reformulating Old Drugs as Investors Say ‘Show Me’
- The Top Ten Stocks for May 20
- Actavis to Buy Warner Chilcott in Women’s Health Effort
- Lupin Plunges Most in 2 Years as Credit Suisse Downgrades Stock
- S&P 500 Stocks Biggest Weekly Changes in Target Price
- Billionaire Frost Props Up Prolor Bid With Stock Buys
- Sebelius Limited Fundraising For Health Law to Two Calls
- Teva U.S. Jump Widens Holiday Discount: Israel Overnight
- Activist Investing: Money Moves (05/14)
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page